Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Penicillamine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Penicillamine belongs to a group of medicines called disease modifying antirheumatic drugs (DMARDS). DMARDS work by reducing the body's immune response and the symptoms of rheumatoid arthritis. Penicillamine helps to relieve the pain and stiffness caused by rheumatoid arthritis. It is used when other medicines for rheumatoid arthritis have not worked. Penicillamine is also a chelating agent. This means that it can bind to certain metals in your body, including lead and copper, to help remove them from your body. Penicillamine is used in adults and children to treat: serious, active rheumatoid arthritis, including Still's disease in children Wilson's disease, a condition where the body cannot get rid of copper properly a kidney problem called cystinuria lead poisoning. Penicillamine is used in adults only to treat: chronic active hepatitis – a type of liver disease. Penicillamine is not a painkiller so you should not expect to feel better straight away. It will be a few weeks before your joints feel less stiff and painful. 2.
e Penicillamine
Your doctor will ask you to have blood tests to check your blood count and kidney function before you start taking Penicillamine. He or she will test your blood and urine regularly while you are taking Penicillamine. This is so that your doctor can check for any side effects and adjust your dose if necessary.
Do not take Penicillamine:
–
if you are allergic to penicillamine or any of the other ingredients of this medicine (listed in section 6) if you have ever had agranulocytosis (reduction in the number of white blood cells) after taking penicillamine if you have ever had aplastic anaemia (a severe reduction in blood cells which can cause weakness, bruising or make infections more likely) after taking penicillamine if you have ever had lupus erythematosus (LE), an allergic condition which causes skin rashes if you suffer from kidney problems if you have thrombocytopenia (a blood disorder which causes bleeding into your skin, bruising and more bleeding than usual after an injury) after taking penicillamine.
If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before you take Penicillamine. Warnings and precautions Talk to your doctor or pharmacist before taking Penicillamine, particularly if any of the following applies to you: if you have ever had side effects with gold or you are currently taking medicines that contain gold if you are receiving concurrently antimalarial drugs such as 4-aminoquinolone drugs like hydroxychloroquine phosphate and chloroquine if you have protein in your urine if you are pregnant, trying to become pregnant or breast-feeding if you have blood in your urine if you have leucopenia (a blood disorder which causes susceptibility to infection) if you are elderly. Your doctor should carry out full blood and urine tests: weekly or fortnightly for the first 8 weeks of treatment, and then monthly whenever your dose of penicillamine is increased. If you are taking Penicillamine for Wilson's disease or for cystinuria, your doctor may carry out these tests at less regular intervals. Your doctor may tell you to stop taking Penicillamine if: your thrombocyte count or your white blood cell count fall below certain levels, or either count falls for three tests in a row. If, after stopping your tablets your blood cell counts return to normal, you may be able to restart treatment at a lower dose. If, after restarting your tablets at a lower dose you develop low blood counts again, you should permanently stop taking this medicine. Other medicines and Penicillamine Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Penicillamine may increase the risk of side effects if you also take the following medicines:
–
iron therapy (used to treat low iron levels or anaemia). Take the iron at least two hours before or after taking Penicillamine antacids (used to neutralise acid in your stomach). Take the antacids at least two hours before or after taking Penicillamine zinc (used to treat low zinc levels), concomitant use may reduce the effect of both medicine.
Penicillamine may affect how well the following medicines work:
penicillamine
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. You will have regular blood and urine tests, especially when you start taking the tablets and when you increase the dose. These are to check for changes in your blood cell counts and to look for protein or blood in your urine. The recommended dose for each condition is given below. Use in adults Rheumatoid Arthritis: Take 125 mg to 250 mg per day for the first month. Your doctor will then tell you how to increase the dose gradually over several months until your symptoms get better. Your doctor will monitor you closely until a minimum daily dose is found that controls your symptoms (your maintenance dose).
This may take some months. The usual maintenance dose is 500 mg to 750 mg per day but may be as high as 1500 mg per day. It may be several months before you feel better. If there is no improvement after taking the tablets for 1 year, your doctor will tell you to stop taking the tablets. If your symptoms are controlled continuously for 6 months, your doctor may reduce your daily dose. Wilson's disease: The recommended dose is between 1500 mg to 2000 mg per day in divided doses. If your symptoms are controlled, your doctor may reduce your dose. You should not take a dose of 2000 mg or more per day for more than 12 months. Cystinuria: Your doctor will take a sample to measure the amount of cystine (an amino acid) in your urine. From this he will be able to work out the lowest dose that will still be effective for you. Prevention of cystine stones: 500 mg to 1000 mg at bedtime. It is important that you drink enough fluids (not less than 3 litres per day). Dissolving cystine stones: 1000 mg to 3000 mg per day, in divided doses. Lead Poisoning: 1000 mg to 1500 mg per day, in divided doses until your doctor tells you that the amount of lead in your urine is normal. Active Chronic Hepatitis: Your doctor should take a blood sample regularly to check that your liver is working well. For maintenance, initially 500 mg per day in divided doses, increasing over 3 months to a maintenance dose of 1250 mg per day. Use in elderly Rheumatoid Arthritis: The recommended dose is 125 mg daily for the first month. Your doctor will then tell you how to increase the dose gradually over several months until you are feeling better. You should not take more than 1000 mg daily. It may be several months before you feel better. If there is no improvement after taking the tablets for 1 year, your doctor will tell you to stop taking the tablets. If you stay well for six months your doctor may reduce your dose. Wilson's disease: Your dose will depend on your weight. The recommended dose is 20 mg a day for each kilogram of body weight in divided doses. Your doctor will reduce the dose over time to find the minimum necessary to control your disease. Cystinuria: Your doctor will determine your dose. Lead poisoning: Your dose will depend on your weight. The recommended dose is 20 mg a day for each kilogram of body weight in divided doses, until your doctor tells you the amount of lead in your blood is normal. Active Chronic Hepatitis: Penicillamine is not recommended for the treatment of active chronic hepatitis in the elderly.
Use in children The dose may depend on the weight of the child. As the smallest available tablet is 125 mg, it might be too large for very small children. Rheumatoid arthritis: The recommended dose is 15 mg to 20 mg a day for each kilogram of body weight. You will start with a low dose for the first month and increase gradually. Wilson's disease: For children under 12 years, 20 mg a day for each kilogram of body weight in two or three separate doses given 1 hour before meals. For older children the usual dose is 750 mg to 1000 mg daily. Cystinuria: The recommended starting dose is 20 mg to 30 mg for each kilogram of body weight, in two or three separate doses given 1 hour before meals. Your doctor may change your dose depending on the results of the tests on your urine. Lead poisoning: The recommended dose is 15 mg to 20 mg a day for each kilogram of body weight, in two or three separate doses. Active Chronic Hepatitis: Penicillamine is not recommended for the treatment of active chronic hepatitis in the paediatric population. If you have kidney problems your doctor will start you on a lower dose. Method of administration When taking Penicillamine:
Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor or go to your nearest hospital emergency department immediately if you think you may have any of the following serious side effects: Common: may affect up to 1 in 10 people
• • •
worsening of the pain and swelling in your joints lupus erythmatosus (an allergic condition which causes joint pain, skin rashes and fever) newly diagnosed rheumatoid arthritis.
After several months or years of therapy you may develop a particular rash that makes your skin fragile called acquired epidermolysis bullosa or penicillamine dermopathy. If you get this your doctor may tell you to take a lower dose. If you suffer from rheumatoid arthritis you should tell your doctor if your joints become more painful, swollen, red or hot because medicines like Penicillamine sometimes cause joint infections. If you suffer from Wilson's disease you should tell your doctor if you experience:
Penicillamine
Keep this medicine out of the sight and reach of children. Store your tablets in a cool, dry place below 25°C. Do not use this medicine after the expiry date which is stated on the bottle after 'EXP'. The expiry date refers to the last day of that month. Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
What Penicillamine film-coated tablets contain The active substance is penicillamine. Each 125 mg tablet contains 125 mg penicillamine. Each 250 mg tablet contains 250 mg penicillamine. The other ingredients are: povidone, lactose, sodium starch glycollate, magnesium stearate. The film-coat contains: hydroxypropyl, methylcellulose (E464), titanium dioxide (E171), polyethylene glycol, carnauba wax. What Penicillamine looks like and contents of the pack Your medicine comes as a round, white film coated tablet. On one side, the 125 mg tablet is embossed with 'PC 125' and marked 'G' on the reverse, the 250 mg is embossed with 'PC 250' on one side and marked 'G' on the reverse. Penicillamine film-coated tablets are available in polypropylene containers with polyethylene caps in packs of 5, 7, 10, 14, 15, 20, 21, 25, 28, 30, 56, 60, 84, 90, 100, 112, 120, 168, 180, 250 and 1000 tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder Mylan, Potters Bar, Herts, EN6 1TL, United Kingdom. Manufacturer Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland. Mylan Hungary Kft, Mylan utca 1, Komȃrom, 2900, Hungary This leaflet was last revised in 05/2026.
Penicillamine 125 mg film-coated tablets comes as tablet containing 125mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Penicillamine 125 mg film-coated tablets is penicillamine.
This leaflet reproduces the patient information leaflet approved for Penicillamine 125 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
1. Severe active rheumatoid arthritis including juvenile forms.
2. Wilson's disease (hepatolenticular degeneration) in adults and children (0 to 18 years).
3. Cystinuria – dissolution and prevention of cystine stones in adults and children (0 to 18 years).
4. Lead poisoning in adults and children (0 to 18 years).
5. Chronic active hepatitis in adults.
Posology
a) Rheumatoid Arthritis
Adults
A daily dose of 125 - 250 mg per day is recommended for the first month, increasing by the same amount every four to twelve weeks until remission occurs. The minimum maintenance dose to achieve suppression of symptoms should be used and treatment should be discontinued if no improvement occurs within 12 months. Improvement may not occur for some months. The usual maintenance dose is 500 mg to 750 mg daily. However, up to 1500 mg daily may be required.
Reduction in maintenance dosage by 125 mg to 250 mg every 12 weeks may be attempted after a period of 6 months continuous remission.
Elderly
The initial dose should not exceed 125 mg daily for the first month, increasing by similar increments every four to twelve weeks until the minimum maintenance dose to supress symptoms is reached. Daily dosage should not exceed 1000 mg (see section 4.4).
Paediatric population
The usual maintenance dose is 15 to 20 mg/kg/day. The initial dose should be lower (2.5 to 5 mg/kg/day) and increased every four weeks over a period of three to six months.
Patients with Renal impairment
Penicillamine therapy should be initiated at a low dose with intervals between dose increase of at least twelve weeks. Fortnightly monitoring for toxicity is mandatory throughout treatment for rheumatoid arthritis.
b) Wilsons Disease
Patients must be maintained in negative copper balance and the minimum dose of Penicillamine required to achieve this should be given.
Adults
1500 mg to 2000 mg daily in divided doses. Dose reduction may be attempted when remission occurs, decreasing to 750 mg to 1000 mg per day. It is advisable that a dose of 2000 mg per day should not be continued for more than 12 months.
Elderly
20 mg/kg/day in divided doses adjusting the dose minimal level necessary to control disease.
Paediatric population
20 mg/kg/day in two or three divided doses, given 1 hour before meals. For older children (>12 years) the usual maintenance dose is 750 mg to 1000 mg daily.
Patients with Renal impairment
Extra precautions should be taken to monitor for adverse effects in patients with Wilson's disease and renal insufficiency.
c) Cystinuria
The lowest effective dose should be used and this is determined by quantitative amino acid chromatography of urine.
(i) Dissolution of cystine stones
Adults
1000 mg to 3000 mg daily, in divided doses. Cystine levels in urine should not exceed 200 mg/litre.
(ii) Prevention of cystine stones
Adults
500 mg to 1000 mg at bedtime. Maintenance of adequate fluid intake (not less than 3 litres/day is important). Cystine levels in the urine should not exceed 300 mg/litre.
Elderly
Use the minimum dose to maintain urinary cystine levels below 200 mg/litre.
Paediatric population
20 to 30 mg/kg/day in two or three divided doses, given 1 hour prior to meals, adjusted to maintain urinary cystine level below 200 mg/litre.
Patients with Renal impairment
If renal insufficiency is present at the onset of therapy, the starting dose should be lower, but it will be necessary to give sufficient Penicillamine to achieve urine cystine levels of not more than 300 mg/litre. The maintenance dose should be reviewed at intervals of not more than four weeks.
d) Lead Poisoning
Adults
1000 mg to 1500 mg daily, in divided doses until urinary lead is stabilised at less than 0.5 mg per day.
Elderly
20 mg/kg/day in divided doses until lead levels in the urine is stabilised at less than 0.5 mg per day.
Paediatric population
Penicillamine should only be used in cases where blood lead levels <45 mcg/dL. A total of 15 – 20 mg/kg/day in 2 – 3 doses should be used.
e) Chronic active hepatitis
Adults
For maintenance treatment after the disease process has been brought under control with corticosteroids. The initial dose of 500 mg daily in divided doses, should be increased gradually over three months to a maintenance dose of 1250 mg daily. During this period, the dose of corticosteroids should be phased out. Throughout therapy, liver function tests should be carried out periodically to assess the disease status.
Elderly
Not recommended.
Paediatric population
The safety and efficacy of penicillamine in children less than 18 years with chronic active hepatitis has not been established. No data are available.
Method of administration
For oral administration.
Penicillamine should be taken on an empty stomach at least half an hour before meals in adults and one hour before meals in paediatric patients, or on retiring.
As the smallest available tablet is 125 mg, this might not be suitable for very young children.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Agranulocytosis, aplastic anaemia or severe thrombocytopenia due to penicillamine.
Lupus erythematosus.
Moderate or severe renal impairment.
Full blood and platelet counts should be performed and renal function should be assessed prior to treatment with penicillamine.
Monitoring of blood and platelet counts should be carried out at appropriate intervals, together with urinalysis for detection of haematuria and proteinuria (see section 4.8). Urinalysis should be carried out weekly at first, and following each increase in dose, then monthly, although longer intervals may be adequate for cystinuria and Wilson's disease. Increasing or persistent proteinuria may necessitate withdrawal of therapy.
During the first eight weeks of therapy full blood counts should be carried out weekly or fortnightly and also in the week after any increase in dose, otherwise monthly thereafter. In cystinuria or Wilson's disease, longer intervals may be adequate.
If platelets fall below 120,000 per mm3 or white blood cells below 2,500 per mm3, or if three consecutive falls are noted within the normal range, withdrawal of treatment should be considered. When counts return to normal, treatment may be restarted at a reduced dosage, but should be permanently withdrawn on recurrence of leucopenia or thrombocytopenia. Penicillamine may potentiate the bone marrow suppression caused by clozapine.
Care should be taken and dosage modified, if needed, in patients with renal impairment (see section 4.2).
Especially careful monitoring is necessary in older people since increased toxicity has been observed in this patient population regardless of renal function.
Concomitant use of NSAIDs and other nephrotoxic drugs may increase the risk of renal damage (see section 4.5).
Penicillamine should be used with caution in patients who have had adverse reactions to gold.
Concomitant or previous treatment with gold may increase the risk of side effects with penicillamine treatment. Therefore penicillamine should be used with caution in patients who have previously had adverse reactions to gold and concomitant treatment with gold should be avoided (see section 4.5).
Penicillamine should not be used in patients who are receiving concurrently antimalarial drugs such as hydroxychloroquine phosphate, chloroquine. These drugs having similar hematologic and renal adverse reactions, could act synergistically when used together with penicillamine (See section 4.5).
If concomitant oral iron, digoxin or antacid therapy is indicated, this should not be given within two hours of taking penicillamine (see section 4.5).
Antihistamines, steroid cover, or temporary reduction of dose will control urticarial reactions (see section 4.8).
Reversible loss of taste may occur. Mineral supplements to overcome this are not recommended (see section 4.8).
Haematuria is rare, but if it occurs in the absence of renal stones or other known causes, treatment should be stopped immediately (see section 4.8).
A late rash, described as acquired epidermolysis bullosa and penicillamine dermopathy, may occur after several months or years of therapy. This may necessitate a reduction in dosage (see section 4.8).
Breast enlargement has been reported as a rare complication of penicillamine therapy in both women and men (see section 4.8). Danazol has been used successfully to treat breast enlargement which does not regress on drug discontinuation.
The use of DMARDs, including penicillamine, has been linked to the development of septic arthritis in patients with rheumatoid arthritis, although rheumatoid arthritis is a stronger predictor for the development of septic arthritis than the use of a DMARD (see section 4.8).
Deterioration of the neurological symptoms of Wilson's disease (dystonia, rigidity, tremor, dysarthria) have been reported following introduction of penicillamine in patients treated for this condition. This may be a consequence of mobilisation and redistribution of copper from the liver to the brain (see section 4.8).
Pyridoxine daily may be given to patients on long term therapy, especially if they are on a restricted diet, since penicillamine increases the requirement of this vitamin (see section 4.5).
These tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Concomitant use of iron or antacids: oral absorption of penicillamine may be reduced by concomitant administration of iron or antacid (see section 4.4).
Concomitant use of digoxin: oral absorption of digoxin may be reduced by concomitant administration of penicillamine (see section 4.4).
Concomitant use of NSAIDs and other nephrotoxic drugs may increase the risk of renal damage (see section 4.4).
Concomitant use of antimalarial drugs such as hydroxychloroquine phosphate, chloroquine: These drugs having similar hematologic and renal adverse reactions, could act synergistically when used together with penicillamine. (see section 4.4).
Concomitant use of gold: concomitant use is not recommended (see section 4.4).
Concomitant use of clozapine: penicillamine may potentiate the blood dyscrasias seen with clozapine (see section 4.4).
Concomitant use of zinc: oral absorption of penicillamine may be reduced by concomitant administration of zinc; absorption of zinc may also be reduced by penicillamine.
Pyridoxine daily may be given to patients on long term therapy, especially if they are on a restricted diet, since penicillamine increases the requirement for this vitamin (see section 4.4).
Pregnancy
The safety of penicillamine for use during pregnancy has not been established (see section 5.3).
Wilson's disease: There have been several cases of reversible cutis laxa in infants born to mothers taking penicillamine throughout pregnancy. Although there have been no controlled studies on the use of penicillamine during pregnancy, two retrospective studies have reported the successful delivery of 43 normal infants to 28 women receiving between 500 mg and 2000 mg of penicillamine daily. There are also anecdotal reports both of congenital abnormalities and of successful outcomes in patients who have remained on penicillamine during pregnancy. If treatment with penicillamine is to be continued following a risk-benefit analysis, consideration should be given to reducing the dose of penicillamine to the lowest effective dose.
Cystinuria: Whilst normal infants have been delivered, there is one report of a severe connective tissue abnormality in the infant of a mother who received 2000 mg penicillamine daily throughout pregnancy. Whenever possible, penicillamine should be withheld during pregnancy, but if stones continue to form, the benefit of resuming treatment must be weighed against the possible risk to the foetus.
Rheumatoid arthritis or chronic active hepatitis: Penicillamine should not be administered to patients who are pregnant, and therapy should be stopped when pregnancy is diagnosed or suspected, unless considered to be absolutely essential by the physician.
Breast-feeding
Due to the lack of data on the use in breast-feeding patients and the possibility that penicillamine may be transmitted to newborns through breast milk, penicillamine should only be used in breast-feeding patients when it is considered absolutely essential by the physician.
None known.
The most common of all side-effects are thrombocytopenia and proteinuria.
Thrombocytopenia occurs commonly. The reaction may occur at any time during treatment and is usually reversible.
Proteinuria occurs in up to 30% of patients and is partially dose-related (see section 4.4).
Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1000, < 1/100), rare (≥ 1/10,000, < 1/1000), very rare (< 1/10,000) and not known (frequency cannot be estimated from the available data).
The incidence and severity of some of the adverse reactions, noted below, varies according to the dosage and nature of the disease under treatment.
Blood and lymphatic system disorders
Common:
Not known:
Thrombocytopenia.
Neutropenia 8, agranulocytosis 1, aplastic anaemia 1, haemolytic anaemia, leucopenia.
Immune system disorders
Rare:
Allergic reactions including hypersensitivity.
Metabolism and nutrition disorders
Not known:
Anorexia 2.
Nervous system disorders
Not known:
Loss of taste 4.
Vascular disorders
Not known:
Pulmonary haemorrhage, vasculitis.
Respiratory, thoracic and mediastinal disorders
Not known:
Inflammatory conditions of the respiratory tract such as bronchiolitis, pneumonitis, yellow nail syndrome.
Gastrointestinal disorders
Rare:
Not known:
Mouth ulceration, stomatitis.
Pancreatitis, nausea 2, vomiting.
Hepatobiliary disorders
Not known:
Cholestatic jaundice.
Skin and subcutaneous tissue disorders
Rare:
Not known:
Alopecia, pseudoxanthoma elasticum, elastosis perforans, skin laxity.
Rashes 2, urticarial reactions 3, dermatomyositis, pemphigus, Stevens-Johnson syndrome, acquired epidermolysis bullosa 6, penicillamine dermopathy 6.
Musculoskeletal and connective tissue disorders
Not known:
Drug induced lupus erythematosus, myasthenia gravis, polymyositis, rheumatoid arthritis.
Renal and urinary disorders
Very common:
Rare:
Not known:
Proteinuria.
Haematuria 5.
Nephrotic syndrome, glomerulonephritis, Goodpasture's syndrome.
Reproductive system and breast disorders
Rare:
Breast enlargement 7.
General disorders and administration site conditions
Not known:
Fever 2.
1. Deaths from agranulocytosis and aplastic anaemia have occurred.
2. Nausea, anorexia, fever and rash may occur early in therapy, especially when full doses are given from the start.
3. Antihistamines, steroid cover, or temporary reduction of dose will control urticarial reactions (see section 4.4).
4. Reversible loss of taste may occur. Mineral supplements to overcome this are not recommended (see section 4.4).
5. Haematuria is rare, but if it occurs in the absence of renal stones or other known cause, treatment should be stopped immediately (see section 4.4).
6. A late rash, described as acquired epidermolysis bullosa and penicillamine dermopathy, may occur after several months or years of therapy (see section 4.4).
7. Breast enlargement has been reported as a rare complication of penicillamine therapy in both women and men (see section 4.4).
8. The reaction may occur at any time during treatment and are usually reversible (see section 4.4).
The development of septic arthritis in patients with rheumatoid arthritis has been linked to the use of DMARDs, including penicillamine (see section 4.4).
Deterioration of the neurological symptoms of Wilson's disease (dystonia, rigidity, tremor, dysarthria) have been reported following the introduction of penicillamine in patients treated for this condition (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
There are no reported cases of undesirable reactions to penicillamine overdosage and no special treatment is recommended.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Penicillamine 125 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.